nivolumab
bms
['cm816']
#esmo22 disappointing but not unexpected data from #cm816 - if residual disease is seen in both ln and primary at resection post chemo/io, only 20% of patients remain relapse-free at 33months. this cohort represent 2/3 of patients in chemo/io arm. 
Oncology Dr and sports nut. Currently working at Beaumont Hospital